Ghayas C. Issa, MD, MS
Department of Leukemia, Division of Cancer Medicine
About Dr. Ghayas C. Issa
Dr. Issa is a clinical and translational researcher in the Departments of Leukemia and Genomic Medicine at the MD Anderson Cancer Center in Houston, Texas. His work focuses on the genetic underpinnings of leukemia to uncover therapeutic vulnerabilities, mechanisms of disease progression, and treatment response. Through this research, he aims to develop safe and effective targeted therapies.
His clinical research centers on menin inhibitors, a novel class of targeted therapies for acute leukemia. He serves as Principal Investigator on numerous investigator-initiated studies and multi-institutional clinical trials, which led to the FDA approval of the menin inhibitor revumenib for KMT2A-rearranged acute leukemia. He is also a lead investigator or steering committee member for global phase 3 trials evaluating menin inhibition in combination with standard of care for newly diagnosed acute myeloid leukemia. At MD Anderson, Dr. Issa leads a precision medicine program for acute leukemias susceptible to menin inhibition, focusing on biomarker discovery, measurable residual disease assays, resistance mechanisms, and rational combination therapies.
His research has been published in high-impact journals including Nature, New England Journal of Medicine, Cell, Journal of Clinical Oncology, Lancet Oncology, and Blood. Dr. Issa’s work has been recognized with numerous honors, including the ASCO Young Investigator Award, the TRTH Award from ASH and EHA, the Paul Calabresi K12 Award, the MD Anderson Faculty Scholar Award, and the Andrew Sabin Award.
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Associate Professor, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2023 | The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, US, Biomedical Sciences – Cancer Biology, MS |
| 2010 | Saint Joseph University Faculty of Medicine, Beirut, LB, MD |
| 2007 | Saint Joseph University Faculty of Medicine, Beirut, LB, Certificate in Immunology |
Postgraduate Training
| 2014-2017 | Clinical Fellowship, Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2011-2014 | Clinical Residency, Internal Medicine, Mount Sinai Beth Israel, New York, New York |
| 2010-2011 | Research Fellow, Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts |
Licenses & Certifications
| 2017 | Texas Medical Board |
| 2017 | American Board of Internal Medicine, Medical Oncology |
| 2017 | American Board of Internal Medicine, Hematology |
| 2014 | American Board of Internal Medicine, Internal Medicine |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - 2024
Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2024
Instructor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2018
Other Professional Positions
Member, MD Anderson Cancer Center Support Grant Developmental Therapeutics Program (NCI), Houston, TX, 2023 - Present
Member, Global Steering Committee for the phase III Multi-Center, Open-Label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients with Newly Diagnosed CML, Houston, TX, 2021 - Present
Member, Global Safety Monitoring Committee for the Phase 1 ziftomenib (KO-539) in combination, Houston, TX, 2013 - Present
Institutional Committee Activities
Member, Precision Oncology Decision Support team, 2022 - Present
Member, Academic Review Committee for the Division of Education & Training, 2022 - Present
Honors & Awards
| 2025 | Sabin Award, The University of Texas MD Anderson Cancer Center |
| 2024 | Faculty Scholar Award, The University of Texas MD Anderson Cancer Center |
| 2023 | Paper Selected for Wall of Science, The University of Texas MD Anderson Cancer Center |
| 2018 | Paul Calabresi Clinical Oncology Award (K12), NIH |
| 2018 | Translational Research Training in Hematology Award, European Hematology Association and the American Society of Hematology |
| 2017 | The Kimberly Patterson Leukemia Research Fellowship, The University of Texas MD Anderson Cancer Center |
| 2017 | Future Leaders Award for Clinical Research in Hematology, Celgene |
| 2016 | Molecular Biology in Clinical Oncology, 25th Annual AACR Workshop, American Association for Cancer Research |
| 2016 | Young Investigator Award, American Society of Clinical Oncology |
| 2015 | Abstract Achievement Award,, American Society of Hematology |
| 2011 | Abstract Achievement Award, American Society of Hematology |
| 2008 | Scholar In Training Award, American Association for Cancer Research |
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2023. The Future of Menin Inhibitors in AML. Conference. The Future of Menin Inhibitors in AML, US.
- 2023. Therapeutic Implications of Menin Inhibition. Conference. Therapeutic Implications of Menin Inhibition, US.
- 2023. Epigenetic targeting of leukemia using menin inhibitors. Conference. Epigenetic targeting of leukemia using menin inhibitors, US.
- 2023. Therapeutic Implications of Menin Inhibition. Conference. Therapeutic Implications of Menin Inhibition, US.
- 2023. Clinical Development in Rare Cancers: Menin Inhibitors. Conference. Clinical Development in Rare Cancers: Menin Inhibitors, US.
- 2022. The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study. Conference. The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study, US.
- 2022. Outcomes After Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) Leukemia Patients Achieving Remissions After Menin Inhibition: Revumenib (SNDX-5613) Ph1 Experience. Conference. Outcomes After Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) Leukemia Patients Achieving Remissions After Menin Inhibition: Revumenib (SNDX-5613) Ph1 Experience, US.
- 2017. Clinical and Molecular Characterization of Clonal Chromosomal Abnormalities Appearing in Philadelphia-Negative Metaphases of Chronic Phase CML. Conference. Clinical and Molecular Characterization of Clonal Chromosomal Abnormalities Appearing in Philadelphia-Negative Metaphases of Chronic Phase CML, US.
Grant & Contract Support
| Date: | 2023 - 2025 |
| Title: | Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia |
| Funding Source: | Kura Oncology |
| Role: | PI |
| Date: | 2023 - Present |
| Title: | Impact of Non-ABL Mutations on Outcomes of CML |
| Funding Source: | Scurlock Foundation |
| Role: | PI |
| ID: | 123515 |
| Date: | 2022 |
| Title: | Augment-102: a phase 1, open-label, dose-escalation study to evaluate safety, tolerability and preliminary anti-leukemic activity of SNDX-5613 in combination with chemotherapy in patients with relapsed/refractory leukemias harboring a KMT2A/MLL gene rearrangement or nucleophosmin 1 mutation (mnpm1) |
| Funding Source: | Syndax |
| Role: | PI |
| ID: | 14717 |
| Date: | 2022 - 2025 |
| Title: | A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) |
| Funding Source: | Astex Pharmaceuticals |
| Role: | PI |
| ID: | 14351 |
| Date: | 2022 - 2029 |
| Title: | A Phase 1, Open-label Study to Assess the Mass Balance, Pharmacokinetics, and Metabolism of Orally Administered (14C)-SNDX-5613 in Patients With Relapsed/Refractory Acute Leukemia |
| Funding Source: | Syndax |
| Role: | PI |
| ID: | 14220 |
| Date: | 2022 - 2027 |
| Title: | A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fmslike tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) |
| Funding Source: | Cullinan Florentine Corp |
| Role: | PI |
| ID: | 13360 |
| Date: | 2022 - Present |
| Title: | Single-cell Analysis in NUP98r Acute Leukemia |
| Funding Source: | Diego Osio-Llerenas Fund |
| Role: | PI |
| ID: | 1234304 |
| Date: | 2021 - 2028 |
| Title: | A Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of MK-0482 in Participants with Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia |
| Funding Source: | Merck Sharp and Dohme Corp |
| Role: | PI |
| ID: | 13486 |
| Date: | 2021 - 2030 |
| Title: | A Phase III, Multi-Center, Open-Label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase |
| Funding Source: | Novartis |
| Role: | PI |
| ID: | 13913 |
| Date: | 2021 - 2024 |
| Title: | Eradicating Minimal Residual Disease in Chronic Myeloid Leukemia |
| Funding Source: | American Society of Hematology (ASH) |
| Role: | PI |
| Date: | 2021 - 2023 |
| Title: | An open label, multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation |
| Funding Source: | Novartis |
| Role: | PI |
| ID: | 12431 |
| Date: | 2021 - 2022 |
| Title: | Single-cell DNA/Protein Analysis (Mission Bio Tapestri) and CyTOF Monitoring of Menin Inhibition Clinical Trial |
| Funding Source: | Syndax |
| Role: | PI |
| Date: | 2020 - 2027 |
| Title: | A Phase 1/2A First in Human Study of the Menin-MLL (KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia |
| Funding Source: | Kura Oncology, Inc |
| Role: | PI |
| ID: | 11760 |
| Date: | 2020 - 2023 |
| Title: | Eradicating Minimal Residual Disease in Chronic Myeloid Leukemia |
| Funding Source: | American Society of Hematology (ASH) |
| Role: | PI |
| Date: | 2020 - Present |
| Title: | Phase 1/2, Open-Label, Dose-Escalation and expansion cohort study of SNDX-5613 in Relapsed/refractory acute leukemia |
| Funding Source: | Syndax Pharma |
| Role: | PI |
| Date: | 2020 - Present |
| Title: | Start-up Funds |
| Funding Source: | MDACC |
| Role: | PI |
| Date: | 2020 - 2024 |
| Title: | Dual targeting of BCR-ABL in CML by adding the allosteric inhibitor ABL001 |
| Funding Source: | Novartis |
| Role: | PI |
| Date: | 2018 - 2019 |
| Title: | Investigating the Expression of the Luteinizing Hormone Receptor in the Hematopoietic Stem Cells of Patients with Leukemia |
| Funding Source: | Leukemia Texas |
| Role: | PI |
| Date: | 2017 - 2019 |
| Title: | Leukemia SPORE Career Development Award |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5-P50-CA100632-15 |
| Date: | 2016 - 2018 |
| Title: | The Impact of Clonal Heterogeneity on Relapse after Hematopoietic Stem Cell Transplant in Patients with Acute Myeloid Leukemia |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | PI |
| Title: | A Multi-site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib |
| Funding Source: | Break Through Cancer, Syndax, Abbvie |
| Role: | PI |
| Title: | A Phase II Study of the Menin Inhibitor Revumenib in Acute Leukemia Associated with HOX gene Upregulation |
| Funding Source: | Syndax |
| Role: | PI |
| Title: | Refining precision medicine for menin-dependent acute leukemias |
| Funding Source: | Hyundai Hope On Wheels |
| Role: | PI |
| Title: | Investigating the Genomic and Epigenomic Mechanisms of Chronic Myeloid Leukemia Transformation from Chronic to Blast Phase |
| Funding Source: | Damon Runyon Cancer Research Foundation |
| Role: | PI |
| ID: | Damon Runyon Physician-Scientist Training Award |
Selected Publications
Peer-Reviewed Articles
- Shi, X, Li, M, Liu, Z, Tiessen, J, Li, Y, Zhou, J, Zhu, Y, Mahesula, S, Ding, Q, Tan, L, Feng, M, Kageyama, Y, Hara, Y, Tao, JJ, Luo, X, Patras, KA, Lorenzi, PL, Huang, S, Stevens, A, Takahashi, K, Issa, GC, Samee, MH, Agathocleous, M, Nakada, D. Guanine nucleotide biosynthesis blockade impairs MLL complex formation and sensitizes leukemias to menin inhibition. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40102405.
- Kadia, TM, Jen, WY, Bataller Torralba, A, Bazinet, A, Borthakur, G, Jabbour, EJ, Qiao, W, Short, NJ, Takahashi, K, Issa, GC, DiNardo, C, Montalban Bravo, G, Pemmaraju, N, Tran, A, Bharathi, V, Loghavi, S, Alousi, AM, Popat, UR, Daver, N, Ravandi-Kashani, F, Kantarjian, HM. A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia. American journal of hematology 100(8):1365-1373, 2025. e-Pub 2025. PMID: 40401707.
- Shen, Q, Haddad, FG, Jabbour, EJ, Tang, G, Fang, H, Liu, M, Hu, AY, Wang, W, Lin, P, Issa, GC, Kantarjian, HM, Medeiros, LJ, Hu, S. Unusually Indolent CML. Clinical Lymphoma, Myeloma and Leukemia 25(8):e580-e590, 2025. e-Pub 2025. PMID: 40345959.
- Berkman, AM, Andersen, C, Puthenpura, V, Short, NJ, Merriman, K, Swaminathan, M, Cuglievan, B, McCall, DC, DiNardo, C, Nunez, CA, Jain, N, Kadia, TM, Issa, GC, Gibson, A, Garcia, MB, Andrew Livingston, J, Parsons, SK, Hildebrandt, MA, Roth, M. Risk of early death after acute leukemia diagnosis among adolescents and young adults. JNCI Cancer Spectrum 9(4), 2025. e-Pub 2025. PMID: 40579211.
- Bataller Torralba, A, Goulart, H, Issa, GC, DiNardo, C, Daver, N, Kadia, TM, Bazinet, A, Bouligny, IM, Senapati, J, Haddad, FG, Borthakur, G, Sasaki, K, Short, NJ, Yilmaz, M, Montalban Bravo, G, Tang, G, Loghavi, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Jabbour, EJ. Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements. Leukemia 39(7):1640-1649, 2025. e-Pub 2025. PMID: 40346311.
- Senapati, J, Loghavi, S, Marvin-Peek, J, Garcia-Manero, G, Kadia, TM, Borthakur, G, Daver, N, Short, NJ, Jain, N, Issa, GC, Haddad, FG, Hammond, D, Chien, KS, Tang, G, Thakral, B, Montalban Bravo, G, Pemmaraju, N, Bazinet, A, Swaminathan, M, Pierce, S, Abbas, HA, Reville, PK, Popat, UR, Shpall, EJ, Champlin, RE, Jabbour, EJ, Ravandi-Kashani, F, Kantarjian, HM, DiNardo, C. Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia. American journal of hematology 100(5):758-769, 2025. e-Pub 2025. PMID: 39921561.
- DiNardo, C, Jen, WY, Takahashi, K, Kadia, TM, Loghavi, S, Daver, N, Xiao, L, Reville, PK, Issa, GC, Short, NJ, Sasaki, K, Wang, S, Mullin, JK, Pierce, S, Bradley, C, Borthakur, G, Maiti, A, Alvarado, Y, Pemmaraju, N, Ferrajoli, A, Swaminathan, M, Ohanian, M, Abbas, HA, Hammond, D, Burger, JA, Haddad, FG, Montalban Bravo, G, Chien, KS, Masarova, L, Yilmaz, M, Jain, N, Andreeff, M, Garcia-Manero, G, Kornblau, SM, Ravandi-Kashani, F, Jabbour, EJ, Konopleva, M, Kantarjian, HM. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39(4):854-863, 2025. e-Pub 2025. PMID: 40000842.
- Haddad, FG, Sasaki, K, Senapati, J, Hu, S, Dellasala, S, Issa, GC, Jabbour, EJ, Kantarjian, HM. Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase. Clinical Lymphoma, Myeloma and Leukemia 25(4):254-257, 2025. e-Pub 2025. PMID: 39592322.
- Bataller Torralba, A, Sasaki, K, Urrutia, S, Montalban Bravo, G, Bazinet, A, Chien, KS, Hammond, DE, Bouligny, IM, Swaminathan, M, Issa, GC, Short, NJ, Daver, N, DiNardo, C, Kadia, TM, Jabbour, EJ, Ravandi-Kashani, F, Roboz, G, Savona, MR, Griffiths, EA, McCloskey, J, Odenike, O, Oganesian, A, Keer, HN, Azab, M, Kantarjian, HM, Garcia-Manero, G. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 40164584.
- Bazinet, A, Bataller Torralba, A, Kadia, TM, Daver, N, Short, NJ, Yilmaz, M, Sasaki, K, DiNardo, C, Borthakur, G, Issa, GC, Bouligny, IM, Pierce, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM. A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia. Cancer 131(6), 2025. e-Pub 2025. PMID: 40097915.
- Wei, Q, Toruner, GA, Thakral, B, Patel, KP, Pemmaraju, N, Wang, S, Kanagal Shamanna, R, Tang, G, Issa, GC, Loghavi, S, Medeiros, LJ, DiNardo, C. Cryptic KMT2A::AFDN Fusion Due to AFDN Insertion into KMT2A in a Patient with Acute Monoblastic Leukemia. Genes 16(3), 2025. e-Pub 2025. PMID: 40149468.
- Jen, WY, Sasaki, K, Ravandi-Kashani, F, Kadia, TM, Wang, S, Wang, W, Loghavi, S, Daver, N, DiNardo, C, Issa, GC, Abbas, HA, Nasnas, C, Bataller Torralba, A, Urrutia, S, Karrar, OS, Pierce, S, Kantarjian, HM, Short, NJ. Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy. Blood Advances 9(4):783-792, 2025. e-Pub 2025. PMID: 39631072.
- Jen, WY, Marvin-Peek, J, Kantarjian, HM, Alvarado, Y, Borthakur, G, Jabbour, EJ, Wierda, WG, Kadia, TM, Daver, N, DiNardo, C, Short, NJ, Jain, N, Ferrajoli, A, Kornblau, SM, Yilmaz, M, Ohanian, M, McCue, D, Burger, JA, Hammond, DE, Patel, K, Issa, GC, Pemmaraju, N, Sasaki, K, Maiti, A, Abbas, HA, Chien, KS, Takahashi, K, Haddad, FG, Bose, P, Masarova, L, Montalban Bravo, G, Swaminathan, M, Brandt, M, Pierce, S, Garcia-Manero, G, Ravandi, F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1), 2025. e-Pub 2025. PMID: 39584789.
- Issa, GC, Aldoss, I, Thirman, MJ, DiPersio, JF, Arellano, M, Blachly, JS, Mannis, GN, Perl, AE, Dickens, DS, Mcmahon, C, Traer, E, Zwaan, CM, Grove, CS, Stone, RM, Shami, PJ, Mantzaris, I, Greenwood, M, Shukla, N, Cuglievan, B, Kovacsovics, T, Gu, Y, Bagley, RG, Madigan, K, Chudnovsky, Y, Van Nguyen, H, McNeer, N, Stein, EM. Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). Journal of Clinical Oncology 43(1):75-84, 2025. e-Pub 2025. PMID: 39121437.
- Short, NJ, Nguyen, D, Jabbour, EJ, Senapati, J, Zeng, Z, Issa, GC, Abbas, HA, Nasnas, C, Qiao, W, Huang, X, Borthakur, G, Chien, KS, Haddad, FG, Pemmaraju, N, Karrar, OS, Nguyen, D, Konopleva, M, Kantarjian, HM, Ravandi, F. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia. The Lancet Haematology 11(11):e839-e849, 2024. e-Pub 2024. PMID: 39303729.
- McCall, DC, Alqahtani, S, Budak, M, Sheikh, IN, Fan, AE, Ramakrishnan, R, Nunez, CA, Roth, M, Garcia, M, Gibson, A, Daver, N, Garces, S, Short, NJ, Issa, GC, Ravandi-Kashani, F, DiNardo, C, Montalban Bravo, G, Garcia-Manero, G, Cuglievan, B, Kadia, TM. Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients. Cancers 16(22), 2024. e-Pub 2024. PMID: 39594839.
- Wang, ES, Issa, GC, Erba, HP, Altman, JK, Montesinos, P, DeBotton, S, Walter, RB, Pettit, K, Savona, MR, Shah, MV, Kremyanskaya, M, Baer, MR, Foran, J, Schiller, GJ, Ades, L, Heiblig, M, Berthon, C, Peterlin, P, Rodríguez-Arbolí, E, Salamero, O, Patnaik, MM, Papayannidis, C, Grembecka, J, Cierpicki, T, Clegg, B, Ray, JM, Linhares, BM, Nie, K, Mitra, A, Ahsan, JM, Tabachri, M, Soifer, HS, Corum, D, Leoni, M, Dale, S, Fathi, AT. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001). The lancet oncology 25(10):1310-1324, 2024. e-Pub 2024. PMID: 39362248.
- Sameeta, F, Fang, H, Wang, W, Tang, Z, Wang, S, Toruner, GA, Parisi, X, Khoury, J, Issa, GC, Garcia-Manero, G, Medeiros, LJ, Tang, G, Loghavi, S. Myeloid neoplasm with <10% blasts and t(3;5)(q25.1;q34)/NPM::MLF1: A classification dilemma. American journal of hematology 99(9):1827-1829, 2024. e-Pub 2024. PMID: 38440855.
- McCall, DC, Abuasab, T, Rodriguez-Sevilla, JJ, Mohamed, SF, Patnaik, A, Devireddy, K, Arani, N, Sheikh, IN, Jamshidi, R, Gibson, A, Roth, M, Nunez, CA, Garcia, M, Chien, KS, Loghavi, S, Pierce, S, Sasaki, K, Issa, GC, Cuglievan, B, Kantarjian, H, Garcia-Manero, G. Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms. Leukemia Research 144, 2024. e-Pub 2024. PMID: 39178611.
- Jabbour E, Haddad FG, Sasaki K, Carter BZ, Alvarado Y, Nasnas C, Nasr L, Masarova L, Daver N, Pemmaraju N, Short NJ, Skinner J, Kadia T, Borthakur G, Garcia-Manero G, Ravandi F, Issa GC, Andreeff M, Kantarjian H. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer 130(15):2652-2659, 2024. e-Pub 2024. PMID: 38591430.
- Akiyama, H, Kantarjian, HM, Jabbour, EJ, Issa, GC, Haddad, FG, Short, NJ, Hu, S, Ishizawa, J, Andreeff, M, Sasaki, K. Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia. International journal of hematology 120(2):203-211, 2024. e-Pub 2024. PMID: 38748089.
- Kantarjian H, Short NJ, Haddad FG, Jain N, Huang X, Montalban-Bravo G, Kanagal-Shamanna R, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Garris R, Nasnas C, Nasr L, Ravandi F, Jabbour E. Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. J Clin Oncol 42(36):JCO2400272, 2024. e-Pub 2024. PMID: 39028925.
- Loghavi S, Wei Q, Ravandi F, Quesada AE, Routbort MJ, Hu S, Toruner GA, Wang SA, Wang W, Miranda RN, Li S, Xu J, DiNardo CD, Daver N, Kadia TM, Issa GC, Kantarjian HM, Medeiros LJ, Tang G. Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia. Am J Hematol 99(10):1959-1968, 2024. e-Pub 2024. PMID: 39016111.
- Issa GC, Stein EM, DiNardo CDD. How I Treat: Differentiation Therapy in Acute Myeloid Leukemia. Blood 145(12):1251-1259, 2024. e-Pub 2024. PMID: 38976876.
- Gener-Ricos G, Bataller A, Rodriguez-Sevilla JJ, Chien KS, Quesada AE, Almanza-Huante E, Hammond D, Sasaki K, DiNardo C, Kadia T, Daver N, Borthakur G, Issa GC, Short NJ, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage. Cancer 130(20):3452-3462, 2024. e-Pub 2024. PMID: 38896064.
- Gener-Ricos G, Bewersdorf JP, Loghavi S, Bataller A, Goldberg AD, Sasaki K, Famulare C, Takahashi K, Issa GC, Borthakur G, Kadia TM, Short NJ, Senapati J, Carter BZ, Patel KP, Kantarjian H, Andreeff M, Stein EM, DiNardo CD. TP53 Y220C mutations in patients with myeloid malignancies. Leuk Lymphoma:1-5, 2024. e-Pub 2024. PMID: 38856690.
- Dinh A, Savoy JM, Kontoyiannis DP, Takahashi K, Issa GC, Kantarjian HM, DiNardo CD, Rausch CR. Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 130(11):1964-1971, 2024. e-Pub 2024. PMID: 38340331.
- Kadia TM, Huang M, Pemmaraju N, Abbas HA, Ly C, Masarova L, Yilmaz M, Lyu MA, Zeng K, Sadeghi T, Cook R, DiNardo CD, Daver N, Issa GC, Jabbour E, Borthakur G, Jain N, Garcia-Manero G, Parmar S, Flowers C, Kantarjian H, Verstovsek S. Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes. NEJM Evid 3(6):EVIDoa2300362, 2024. e-Pub 2024. PMID: 38804782.
- Jen WY, Sasaki K, Loghavi S, Wang SA, Qiao W, Borthakur G, Ravandi F, Kadia TM, Issa GC, Short NJ, Yilmaz M, Daver NG, DiNardo CD. Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression. Br J Haematol 204(6):2259-2263, 2024. e-Pub 2024. PMID: 38603594.
- Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D, Issa GC, Larson RA, Bombaci F, Kapoor S, McCulloch T, Malek K, Yau L, Ifrah S, Hoch M, Cortes JE, Hughes TP. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med 391(10):885-898, 2024. e-Pub 2024. PMID: 38820078.
- Haddad FG, Sasaki K, Nasr L, Short NJ, Kadia T, Dellasala S, Cortes J, Nicolini FE, Issa GC, Jabbour E, Kantarjian H. Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase. Cancer 130(19):3344-3352, 2024. e-Pub 2024. PMID: 38804723.
- Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica 109(11):3543-3556, 2024. e-Pub 2024. PMID: 38695144.
- Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. J Clin Oncol 42(13):1499-1508, 2024. e-Pub 2024. PMID: 38277619.
- Issa GC. The development of menin inhibitors in AML and ALL. Clin Adv Hematol Oncol 22(4):185-187, 2024. e-Pub 2024. PMID: 38739722.
- Nasnas PE, Jabbour EJ, Sasaki K, Issa GC, Masarova L, Short NJ, Haddad FG. Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia. Acta Haematol 148(1):105-110, 2024. e-Pub 2024. PMID: 38574468.
- Bazinet, A, Garcia-Manero, G, Short, NJ, Alvarado, Y, Bataller, A, Abuasab, T, Islam, R, Montalbano, K, Issa, GC, Maiti, A, Yilmaz, M, Jain, N, Masarova, L, Kornblau, SM, Jabbour, EJ, Montalban Bravo, G, Rausch, CR, Pierce, S, DiNardo, C, Kadia, TM, Daver, N, Konopleva, M, Huang, X, Kantarjian, HM, Ravandi-Kashani, F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia. The Lancet Haematology 11(4):e276-e286, 2024. e-Pub 2024. PMID: 38452788.
- Bazinet, A, Kantarjian, HM, Bataller, A, Pemmaraju, N, Borthakur, G, Chien, KS, Alvarado, Y, Bose, P, Jabbour, EJ, Yilmaz, M, DiNardo, C, Issa, GC, Montalban Bravo, G, Short, NJ, Sasaki, K, Bull-Linderman, D, Daver, N, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction. The Lancet Haematology 11(4):e287-e298, 2024. e-Pub 2024. PMID: 38548404.
- Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver NG, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol 11(3):e186-e195, 2024. e-Pub 2024. PMID: 38316133.
- Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv 8(4):927-935, 2024. e-Pub 2024. PMID: 38113472.
- Marvin-Peek, J, Sasaki, K, Kontoyiannis, DP, Adachi, JA, Ohanian, M, Takahashi, K, Issa, GC, Kornblau, SM, Abbas, HA. Nontuberculosis mycobacteria (NTM) infections in patients with leukemia. Frontiers in Medicine 11, 2024. e-Pub 2024. PMID: 39149601.
- Senapati, J, Muftuoglu, M, Ishizawa, J, Abbas, HA, Loghavi, S, Borthakur, G, Yilmaz, M, Issa, GC, Dara, S, Basyal, M, Li, L, Naqvi, K, Pourebrahim, R, Jabbour, EJ, Kornblau, SM, Short, NJ, Pemmaraju, N, Garcia-Manero, G, Ravandi-Kashani, F, Khoury, J, Daver, N, Kantarjian, HM, Andreeff, M, DiNardo, C. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia. Blood cancer journal 13(1), 2023. e-Pub 2023. PMID: 37386016.
- Sasaki, K, Haddad, FG, Short, NJ, Jain, N, Issa, GC, Jabbour, EJ, Kantarjian, HM. Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy—The Surveillance, Epidemiology, and End Results database, 2000–2019. Cancer 129(23):3805-3814, 2023. e-Pub 2023. PMID: 37769040.
- Short, NJ, Muftuoglu, M, Ong, F, Nasr, L, Macaron, W, Montalban Bravo, G, Alvarado, Y, Basyal, M, Daver, N, DiNardo, C, Borthakur, G, Jain, N, Ohanian, M, Jabbour, EJ, Issa, GC, Qiao, W, Huang, X, Kanagal Shamanna, R, Patel, KP, Bose, P, Ravandi-Kashani, F, Delumpa, R, Abramova, R, Garcia-Manero, G, Andreeff, M, Cortes, JE, Kantarjian, HM. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. Journal of Hematology and Oncology 16(1), 2023. e-Pub 2023. PMID: 37422688.
- Senapati, J, Urrutia, S, Loghavi, S, Short, NJ, Issa, GC, Maiti, A, Abbas, HA, Daver, N, Pemmaraju, N, Pierce, S, Chien, KS, Sasaki, K, Kadia, TM, Hammond, DE, Borthakur, G, Patel, KP, Ravandi-Kashani, F, Kantarjian, HM, Garcia-Manero, G, DiNardo, C. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood 142(19):1647-1657, 2023. e-Pub 2023. PMID: 37441846.
- Senapati, J, Fiskus, WC, Daver, N, Wilson, NR, Ravandi-Kashani, F, Garcia-Manero, G, Kadia, TM, DiNardo, C, Jabbour, EJ, Burger, JA, Short, NJ, Alvarado, Y, Jain, N, Masarova, L, Issa, GC, Qiao, W, Khoury, J, Pierce, SR, Miller, D, Sasaki, K, Konopleva, M, Bhalla, K, Borthakur, G, Pemmaraju, N. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clinical Cancer Research 29(21):4352-4360, 2023. e-Pub 2023. PMID: 37585491.
- Montalban Bravo, G, Kanagal Shamanna, R, Li, Z, Hammond, DE, Chien, KS, Rodriguez-Sevilla, JJ, Sasaki, K, Jabbour, EJ, DiNardo, C, Takahashi, K, Short, NJ, Issa, GC, Pemmaraju, N, Kadia, TM, Ravandi-Kashani, F, Daver, N, Borthakur, G, Loghavi, S, Pierce, S, Bueso-Ramos, CE, Kantarjian, HM, Garcia-Manero, G. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. British Journal of Haematology 203(4):581-592, 2023. e-Pub 2023. PMID: 37608562.
- Bataller, A, Loghavi, S, Gerstein, YS, Bazinet, A, Sasaki, K, Chien, KS, Hammond, DE, Montalban Bravo, G, Borthakur, G, Short, NJ, Issa, GC, Kadia, TM, Daver, N, Tang, G, Quesada, AE, Patel, KP, Ravandi, F, Fiskus, WC, Mill, CP, Kantarjian, HM, Bhalla, K, Garcia-Manero, G, Oran, B, DiNardo, C. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. American journal of hematology 98(11):1780-1790, 2023. e-Pub 2023. PMID: 37665752.
- Sasaki, K, Morita, K, Kantarjian, HM, Garcia-Manero, G, Jabbour, EJ, Ravandi, F, Konopleva, M, Borthakur, G, Wierda, WG, Daver, N, Takahashi, K, DiNardo, C, Montalban Bravo, G, Issa, GC, Pierce, S, Soltysiak, KA, Tingen, MS, Cortes, JE. Geographic Disparity of Outcome in Patients With Cancer Over Decades. Clinical Lymphoma, Myeloma and Leukemia 23(11):e369-e378, 2023. e-Pub 2023. PMID: 37690903.
- Haddad, FG, Sasaki, K, Bidikian, A, Issa, GC, Kadia, TM, Jain, N, Alvarado, Y, Short, NJ, Pemmaraju, N, Loghavi, S, Patel, KP, Kanagal Shamanna, R, Yilmaz, M, Masarova, L, Jabbour, EJ, Kantarjian, HM. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. American journal of hematology 98(10):1619-1626, 2023. e-Pub 2023. PMID: 37485584.
- Gener-Ricos, G, Haddad, FG, Sasaki, K, Issa, GC, Skinner, J, Masarova, L, Borthakur, G, Alvarado, Y, Garcia-Manero, G, Jabbour, EJ, Kantarjian, HM. Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 23(10):742-748, 2023. e-Pub 2023. PMID: 37308342.
- Bazinet, A, Kantarjian, HM, Arani, N, Popat, U, Bataller, A, Sasaki, K, DiNardo, C, Daver, N, Yilmaz, M, Abbas, HA, Short, NJ, Issa, GC, Jabbour, EJ, Pierce, S, Chen, J, Garcia, R, Konopleva, M, Garcia-Manero, G, Alousi, A, Shpall, EJ, Champlin, RE, Borthakur, G, Ravandi-Kashani, F, Kadia, TM. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. American journal of hematology 98(9):1383-1393, 2023. e-Pub 2023. PMID: 37334870.
- Short, NJ, Jabbour, EJ, Macaron, W, Ravandi-Kashani, F, Jain, N, Kanagal Shamanna, R, Patel, KP, Loghavi, S, Haddad, FG, Yilmaz, M, Issa, GC, Kebriaei, P, Kornblau, SM, Pelletier, S, Flores, W, Matthews, JA, Garris, R, Kantarjian, HM. Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. American journal of hematology 98(8):1196-1203, 2023. e-Pub 2023. PMID: 37183966.
- Short, NJ, Ong, F, Ravandi, F, Nogueras Gonzalez, G, Kadia, TM, Daver, N, DiNardo, C, Konopleva, M, Borthakur, G, Oran, B, Al-Atrash, G, Mehta, RS, Jabbour, EJ, Yilmaz, M, Issa, GC, Maiti, A, Champlin, RE, Kantarjian, HM, Shpall, E, Popat, UR. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Advances 7(14):3573-3581, 2023. e-Pub 2023. PMID: 37104058.
- Nguyen D, Kantarjian HM, Short NJ, Qiao W, Ning J, Cuglievan B, Daver NG, DiNardo CD, Jabbour EJ, Kadia TM, Borthakur G, Garcia-Manero G, Konopleva MY, Andreeff M, Ravandi-Kashani F, Sasaki K, Issa GC. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. Cancer 129(12):1856-1865, 2023. e-Pub 2023. PMID: 36892949.
- Haddad FG, Kantarjian HM, Bidikian A, Jabbour EJ, Short NJ, Ning J, Xiao L, Pemmaraju N, DiNardo CD, Kadia TM, Marx KR, Garcia-Manero G, Ravandi F, Sasaki K, Issa GC. Association between bariatric surgery and outcomes in chronic myeloid leukemia. Cancer 129(12):1866-1872, 2023. e-Pub 2023. PMID: 36882573.
- Trabal, AM, Gibson, A, He, J, McCall, DC, Roth, M, Nunez, CA, Garcia, MB, Buzbee, M, Toepfer, L, Bidikian, A, Daver, N, Kadia, TM, Short, NJ, Issa, GC, Ravandi-Kashani, F, DiNardo, C, Montalban Bravo, G, Garces, S, Marcogliese, A, Paek, H, Dreyer, Z, Brackett, J, Redell, MS, Yi, JS, Garcia-Manero, G, Konopleva, M, Stevens, A, Cuglievan, B. Venetoclax for Acute Myeloid Leukemia in Pediatric Patients. Cancers 15(7), 2023. e-Pub 2023. PMID: 37046645.
- Jabbour EJ, Sasaki K, Haddad FG, Issa GC, Garcia-Manero G, Kadia TM, Jain N, Yilmaz M, DiNardo CD, Patel KP, Kanagal-Shamanna R, Champlin R, Khouri IF, Dellasala S, Pierce SA, Kantarjian H. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol 98(4):658-665, 2023. e-Pub 2023. PMID: 36683287.
- Siddiqui M, Konoplev S, Issa GC, Kantarjian H, Daver N, Ravandi F, Kadia T, Tang G, Wang SA, Thakral B, Medeiros LJ, Pozdnyakova O, Pierce S, Montalban-Bravo G, Chien K, Hammond D, Sasaki K, Garcia-Manero G, Hasserjian RP. Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements. Am J Hematol 98(4):E91-E94, 2023. e-Pub 2023. PMID: 36661399.
- Bidikian A, Jabbour E, Issa GC, Short NJ, Sasaki K, Kantarjian H. Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor. Am J Hematol 98(4):639-644, 2023. e-Pub 2023. PMID: 36606715.
- Bataller A, Haddad FG, Issa GC, Sasaki K, Jabbour E, Borthakur G, Ferrajoli A, Short NJ. Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring. Leuk Lymphoma 64(3):746-749, 2023. e-Pub 2023. PMID: 36657414.
- Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature 615(7954):920-924, 2023. e-Pub 2023. PMID: 36922593.
- Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv 7(6):933-942, 2023. e-Pub 2023. PMID: 36322818.
- Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol 10(1):e24-e34, 2023. e-Pub 2023. PMID: 36402146.
- Tang Z, Wang W, Yang S, El Achi H, Fang H, Nahmod KA, Toruner GA, Xu J, Thakral B, Ayoub E, Issa GC, Yin CC, You MJ, Miranda RN, Khoury JD, Medeiros LJ, Tang G. 3q26.2/MECOM Rearrangements by Pericentric Inv(3): Diagnostic Challenges and Clinicopathologic Features. Cancers (Basel) 15(2), 2023. e-Pub 2023. PMID: 36672407.
- Abbas HA, Ayoub E, Sun H, Kanagal-Shamanna R, Short NJ, Issa G, Yilmaz M, Pierce S, Rivera D, Cham B, Wing S, Li Z, Hammond D, Jabbour E, Borthakur G, Garcia-Manero G, Andreeff M, Daver N, Kadia T, Konopleva M, DiNardo C, Ravandi F. Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment. Leuk Lymphoma 63(13):1-12, 2022. e-Pub 2022. PMID: 36089905.
- Venugopal S, DiNardo CD, Loghavi S, Qiao W, Ravandi F, Konopleva M, Kadia T, Bhalla K, Jabbour E, Issa GC, Macaron W, Daver N, Borthakur G, Montalban-Bravo G, Yilmaz M, Patel KP, Kanagal-Shamanna R, Chien K, Maiti A, Kantarjian H, Short NJ. Differential Prognostic Impact of RUNX1 Mutations According to Frontline Therapy in Patients with Acute Myeloid Leukemia. Am J Hematol 97(12):1560-1567, 2022. e-Pub 2022. PMID: 36087091.
- Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol 40(33):JCO2102823, 2022. e-Pub 2022. PMID: 35704787.
- Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated AML: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol 97(11):1443-1452, 2022. e-Pub 2022. PMID: 36054614.
- Short NJ, Macaron W, Kadia T, Dinardo C, Issa GC, Daver N, Wang S, Jorgensen J, Nguyen D, Bidikian A, Patel KP, Loghavi S, Konopleva M, Yilmaz M, Jabbour E, Maiti A, Abbas HA, Shpall E, Popat U, Al-Atrash G, Pierce S, Kantarjian HM, Ravandi F. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission. Am J Hematol 97(11):E408-E411, 2022. e-Pub 2022. PMID: 36054774.
- Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H. Low-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol 97(11):1413-1418, 2022. e-Pub 2022. PMID: 36054032.
- Bidikian A, Kantarjian H, Jabbour E, Short NJ, Patel K, Ravandi F, Sasaki K, Issa GC. Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. Blood Cancer J 12(10):144, 2022. e-Pub 2022. PMID: 36307398.
- Levy, MY, Mauro, M, Issa, GC, Andorsky, D, Tomassetti, S, Broun, ER, Maegawa, RO, Deininger, M. CML-427 AIM4CML Trial in Progress. Clinical Lymphoma, Myeloma and Leukemia 22:S298, 2022. e-Pub 2022. PMID: 36163930.
- Abuasab, T, Alvarado, Y, Issa, GC, Islam, R, James, N, Yilmaz, M, Jain, N, Masarova, L, Kornblau, SM, Jabbour, EJ, Pemmaraju, N, Montalban Bravo, G, Pierce, S, DiNardo, C, Kadia, TM, Daver, N, Konopleva, M, Garcia-Manero, G, Ravandi-Kashani, F. AML-328 Phase 2 Study of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Previously Untreated, Older Adult Patients Unfit for Chemotherapy. Clinical Lymphoma, Myeloma and Leukemia 22:S237, 2022. e-Pub 2022. PMID: 36163813.
- Hughes, TP, Cortes, JE, Takahashi, N, Larson, RA, Issa, GC, Bombaci, F, Ramscar, N, Kapoor, S, Ifrah, S, Hochhaus, A. CML-423 Trial in Progress. Clinical Lymphoma, Myeloma and Leukemia 22:S297-S298, 2022. e-Pub 2022. PMID: 36163929.
- Bazinet, A, Kantarjian, HM, Borthakur, G, Yilmaz, M, Bose, P, Jabbour, EJ, Alvarado, Y, Chien, KS, Pemmaraju, N, Takahashi, K, Short, NJ, Daver, N, Issa, GC, Jain, N, Bull-Linderman, D, DiNardo, C, Montalban Bravo, G, Garcia-Manero, G, Sasaki, K, Ravandi-Kashani, F, Kadia, TM. AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S239-S240, 2022. e-Pub 2022. PMID: 36163817.
- Haddad, FG, Kantarjian, HM, Short, NJ, Konopleva, M, Jain, N, Huang, X, Ravandi-Kashani, F, Wierda, WG, Borthakur, G, Sasaki, K, Issa, GC, Alvarado, Y, Pemmaraju, N, Garcia-Manero, G, Thankachan, J, Garris, R, Jabbour, EJ. ALL-424 Updated Results from the Phase II Study of Blinatumomab in Combination With Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S204, 2022. e-Pub 2022. PMID: 36163747.
- Bidikian, A, Kantarjian, HM, Jabbour, EJ, Short, NJ, Ravandi-Kashani, F, Issa, GC, Sasaki, K. CML-288 Impact of ASXL1 Mutations on Prognosis of Chronic Phase Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S291, 2022. e-Pub 2022. PMID: 36163917.
- Bidikian, A, Kantarjian, HM, Dabaja, BS, Ravandi-Kashani, F, Jabbour, EJ, DiNardo, C, Borthakur, G, Daver, N, Garcia-Manero, G, Kadia, TM, Sasaki, K, Issa, GC. AML-285 Association Between Myeloid Malignancies With MECOM Rearrangement and Ocular Adnexal Leukemic Infiltration. Clinical Lymphoma, Myeloma and Leukemia 22:S233-S234, 2022. e-Pub 2022. PMID: 36163805.
- Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 63(9):1-10, 2022. e-Pub 2022. PMID: 35442137.
- Nichols ED, Jabbour E, Jammal N, Chew S, Bryan J, Issa G, Garcia-Manero G, Sasaki K, DiPippo A, Kantarjian H. Real-life incidence of thrombotic events in leukemia patients treated with ponatinib. Am J Hematol 97(9):E350-E352, 2022. e-Pub 2022. PMID: 35759571.
- DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol 97(8):1035-1043, 2022. e-Pub 2022. PMID: 35583199.
- Wang L, Wang W, Beird HC, Cheng X, Fang H, Tang G, Toruner GA, Yin CC, You MJ, Issa GC, Borthakur G, Peng G, Khoury JD, Medeiros LJ, Tang Z. PPP1R7 Is a Novel Translocation Partner of CBFB via t(2;16)(q37;q22) in Acute Myeloid Leukemia. Genes (Basel) 13(8), 2022. e-Pub 2022. PMID: 36011278.
- Zeidan AM, Fenaux P, Gobbi M, Mayer J, Roboz GJ, Krauter J, Robak T, Kantarjian HM, Novák J, Jedrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, Yeh SP, Brandwein JM, Gercheva L, Demeter J, Griffiths EA, Yee KWL, Issa JJ, Bewersdorf JP, Keer H, Hao Y, Azab M, Döhner H. Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. Blood 140(3):285-289, 2022. e-Pub 2022. PMID: 35507690.
- Qiu L, Nunez CA, Tang G, Cuglievan B, Issa GC, Wang SA, Medeiros LJ, Thakral B. A rare case of acute megakaryoblastic leukemia with t(11;17)(q23;q21) and KMT2A::MLLT6 fusion. Ann Hematol 101(7):1579-1581, 2022. e-Pub 2022. PMID: 35091795.
- Haddad F, Kantarjian H, Issa GC, Jabbour E, Sasaki K. Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia. Leuk Lymphoma 63(7):1714-1717, 2022. e-Pub 2022. PMID: 35361036.
- Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, Cortes J, Konopleva M, Pemmaraju N, Alvarado Y, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short NJ, Jabbour E, Kantarjian H. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol 97(7):856-864, 2022. e-Pub 2022. PMID: 35357036.
- Short NJ, Macaron W, Konopleva M, Ravandi F, Jain N, Issa GC, Kadia T, Sasaki K, Kebriaei P, Yilmaz M, Thompson PA, Takahashi K, Abbas HA, Wierda WG, Garris R, Kantarjian HM, Jabbour E. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol 97(6):E201-E204, 2022. e-Pub 2022. PMID: 35266566.
- Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J 12(5):77, 2022. e-Pub 2022. PMID: 35501304.
- Konoplev S, Wang X, Tang G, Li S, Wang W, Xu J, Pierce SA, Jia F, Jorgensen JL, Ravandi F, Issa GC, Medeiros LJ, Wang SA. Comprehensive immunophenotypic study of acute myeloid leukemia with KMT2A (MLL) rearrangement in adults: A single-institution experience. Cytometry B Clin Cytom 102(2):123-133, 2022. e-Pub 2022. PMID: 34964255.
- Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, Dinardo CD, Daver N, Konopleva M, Borthakur G, Shpall EJ, Popat U, Champlin RE, Mehta R, Al-Atrash G, Oran B, Jabbour E, Garcia-Manero G, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Kantarjian H. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol 15(1):12, 2022. e-Pub 2022. PMID: 35093134.
- Venugopal S, Takahashi K, Daver N, Maiti A, Borthakur G, Loghavi S, Short NJ, Ohanian M, Masarova L, Issa G, Wang X, Carlos BR, Yilmaz M, Kadia T, Andreeff M, Ravandi F, Konopleva M, Kantarjian HM, DiNardo CD. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J 12(1):10, 2022. e-Pub 2022. PMID: 35078972.
- Richard-Carpentier G, Kantarjian HM, Tang G, Yin CC, Khoury JD, Issa GC, Haddad F, Jain N, Ravandi F, Short NJ, DiNardo CD, Takahashi K, Konopleva MY, Daver NG, Kadia T, Garcia-Manero G, Garris R, O'Brien S, Jabbour E. Outcomes of Acute Lymphoblastic Leukemia with KMT2A (MLL) rearrangement - The MD Anderson Experience. Blood Adv 5(23):5415-5419, 2021. e-Pub 2021. PMID: 34525185.
- Gibson A, Trabal A, McCall D, Khazal S, Toepfer L, Bell DH, Roth M, Mahadeo KM, Nunez C, Short NJ, DiNardo C, Konopleva M, Issa GC, Ravandi F, Jain N, Borthakur G, Kantarjian HM, Jabbour E, Cuglievan B. Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers (Basel) 14(1), 2021. e-Pub 2021. PMID: 35008312.
- Young PE, Kanagal-Shamanna R, Hu S, Tang G, Thakral B, Daver N, Issa GC, Medeiros LJ, Konoplev S. Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation - First case series from a single institution. Leuk Res 111:106685, 2021. e-Pub 2021. PMID: 34438119.
- Abbas HA, Alaniz Z, Mackay S, Cyr M, Zhou J, Issa GC, Alfayez M, Matthews J, Kornblau SM, Jabbour E, Garcia-Manero G, Konopleva M, Andreeff M, Daver N. Single-cell Polyfunctional Proteomics of CD4 Cells from Patients with AML Predicts Responses to Anti-PD-1-based therapy. Blood Adv 5(22):4569-4574, 2021. e-Pub 2021. PMID: 34555853.
- Alwash Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, Daver N, Ravandi F, Kadia TM, Konopleva M, Dinardo CD, Issa GC, Loghavi S, Takahashi K, Jabbour E, Guerra V, Kornblau S, Kantarjian H, Short NJ. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Am J Hematol 96(11):1420-1428, 2021. e-Pub 2021. PMID: 34351647.
- Dai P, Wu LR, Chen SX, Wang MX, Cheng LY, Zhang JX, Hao P, Yao W, Zarka J, Issa GC, Kwong L, Zhang DY. Calibration-free NGS quantitation of mutations below 0.01% VAF. Nat Commun 12(1):6123, 2021. e-Pub 2021. PMID: 34675197.
- Yang RK, Toruner GA, Wang W, Fang H, Issa GC, Wang L, Quesada AE, Thakral B, Patel KP, Peng G, Liu S, Yin CC, Borthakur G, Tang Z, Wang SA, Miranda RN, Khoury JD, Medeiros LJ, Tang G. CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management. Cancers (Basel) 13(21), 2021. e-Pub 2021. PMID: 34771519.
- DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa GC, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol 39(25):JCO2003736, 2021. e-Pub 2021. PMID: 34043428.
- Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, Short NJ, Haddad F, Tang Z, Patel KP, Cuglievan B, Daver N, DiNardo CD, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Kantarjian HM, Ravandi F. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J 11(9):162, 2021. e-Pub 2021. PMID: 34588432.
- Yilmaz M, Daver N, Borthakur G, Kadia T, DiNardo C, Kanagal-Shamanna R, Loghavi S, Oran B, Popat UR, Pierce S, Jabbour E, Short NJ, Issa GC, Ohanian M, Konopleva M, Patel K, Kantarjian H, Ravandi F. FLT3 inhibitor based induction and allogeneic stem cell transplant in CR1 improves outcomes in patients with newly diagnosed AML with very low FLT3 allelic burden. Am J Hematol 96(8):E275-E279, 2021. e-Pub 2021. PMID: 33891709.
- Morita K, Kantarjian HM, Sasaki K, Issa GC, Jain N, Konopleva M, Short NJ, Takahashi K, DiNardo CD, Kadia TM, Garcia-Manero G, Daver N, Montalban Bravo G, Cortes JE, Ravandi F, Jabbour E. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer 127(15):2641-2647, 2021. e-Pub 2021. PMID: 33823073.
- Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer 127(14):2489-2499, 2021. e-Pub 2021. PMID: 33793970.
- Saxena K, Jabbour E, Issa GC, Sasaki K, Ravandi F, Maiti A, Daver N, Kadia T, DiNardo CD, Konopleva M, Cortes JE, Yilmaz M, Chien K, Pierce S, Kantarjian H, Short NJ. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol 14(1):94, 2021. e-Pub 2021. PMID: 34130720.
- Morita K, Jabbour E, Ravandi F, Borthakur G, Khoury JD, Hu S, Garcia-Manero G, Wierda W, Issa GC, Daver N, Pemmaraju N, Montalban-Bravo G, Soltysiak KA, Pierce S, Bueso-Ramos C, Cortes J, Sasaki K. Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clin Lymphoma Myeloma Leuk 21(5):338-344, 2021. e-Pub 2021. PMID: 33597098.
- Dalle IA, Paranal R, Zarka J, Paul S, Sasaki K, Li W, Ning J, Short NJ, Ohanian M, Cortes JE, Jabbour EJ, Issa GC. Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. Haematologica Online ahead of print(4):0, 2021. e-Pub 2021. PMID: 33297667.
- Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. e-Pub 2021. PMID: 33792630.
- Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2021. PMID: 33264443.
- Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, Cortes JE, Kadia T, Ravandi F, Pierce S, Assi R, Garcia-Manero G, DiNardo CD, Daver N, Pemmaraju N, Kantarjian H, Borthakur G. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia 35(3):691-700, 2021. e-Pub 2021. PMID: 32561839.
- Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov 2(2):125-134, 2021. e-Pub 2021. PMID: 33681815.
- Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106(3):894-898, 2021. e-Pub 2021. PMID: 32499238.
- Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11(2):25, 2021. e-Pub 2021. PMID: 33563904.
- Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Issa GC, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 14(1):34, 2021. e-Pub 2021. PMID: 33618754.
- Sasaki K, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver N, Takahashi K, Naqvi K, DiNardo C, Montalban-Bravo G, Kanagal-Shamanna R, Issa GC, Jain P, Skinner J, Rios MB, Pierce S, Soltysiak KA, Sato J, Garcia-Manero G, Cortes JE. The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. Am J Hematol 96(2):241-250, 2021. e-Pub 2021. PMID: 33180322.
- Yilmaz M, Kantarjian HM, Toruner G, Yin CC, Kanagal-Shamanna R, Cortes JE, Issa G, Short NJ, Khoury JD, Garcia-Manero G, Ravandi F, Kadia T, Konopleva M, Wierda WG, Jain N, Estrov Z, Sasaki K, Pierce S, O'Brien SM, Jabbour EJ. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma 62(1):1-5, 2021. e-Pub 2021. PMID: 32955970.
- Aitken MJL, Benton CB, Issa GC, Sasaki K, Yilmaz M, Short NJ. Two Cases of Possible Familial Chronic Myeloid Leukemia in a Family with Extensive History of Cancer. Acta Haematol 144(5):1-6, 2021. e-Pub 2021. PMID: 33735874.
- Short NJ, Rafei H, Daver N, Hwang H, Ning J, Jorgensen JL, Kadia TM, DiNardo CD, Wang SA, Jabbour E, Popat U, Oran B, Cortes J, Konopleva M, Yilmaz M, Issa GC, Kantarjian H, Ravandi F. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv 4(24):6117-6126, 2020. e-Pub 2020. PMID: 33351107.
- Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia 34(11):2914-2924, 2020. e-Pub 2020. PMID: 32546726.
- Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, Patel KP, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver N, Issa GC, Andreeff M, Kantarjian H, Kadia TM. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv 4(22):5681-5689, 2020. e-Pub 2020. PMID: 33211826.
- Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Issa GC, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 13(1):132, 2020. e-Pub 2020. PMID: 33032648.
- DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
- Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 7(7):e523-e533, 2020. e-Pub 2020. PMID: 32589978.
- Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol 95(6):612-622, 2020. e-Pub 2020. PMID: 32112433.
- Samra B, Richard-Carpentier G, Kadia TM, Ravandi F, Daver N, DiNardo CD, Issa GC, Bose P, Konopleva MY, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes JE, Kantarjian H, Short NJ. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J 10(5):47, 2020. e-Pub 2020. PMID: 32366832.
- Abou Dalle I, Ghorab A, Patel K, Wang X, Hwang H, Cortes J, Issa GC, Yalniz F, Sasaki K, Chihara D, Price A, Kadia T, Pemmaraju N, Daver N, DiNardo C, Ravandi F, Kantarjian HM, Borthakur G. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer J 10(5):48, 2020. e-Pub 2020. PMID: 32366841.
- Short NJ, Kantarjian H, Kanagal-Shamanna R, Sasaki K, Ravandi F, Cortes J, Konopleva M, Issa GC, Kornblau SM, Garcia-Manero G, Garris R, Higgins J, Pratt G, Williams LN, Valentine CC, Rivera VM, Pritchard J, Salk JJ, Radich J, Jabbour E. Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer J 10(5):61, 2020. e-Pub 2020. PMID: 32457305.
- Short NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, Wang F, Assi R, Montalban-Bravo G, Matthews J, Ma W, Loghavi S, Takahashi K, Issa GC, Kornblau SM, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov Z, Ravandi F. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv 4(8):1670-1677, 2020. e-Pub 2020. PMID: 32324887.
- Alotaibi AS, Yilmaz M, Loghavi S, DiNardo C, Borthakur G, Kadia TM, Thakral B, Pemmaraju N, Issa GC, Konopleva M, Short NJ, Patel K, Tang G, Ravandi F, Daver N. Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case Series. Front Oncol 10:588876, 2020. e-Pub 2020. PMID: 33194747.
- Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol 10:582213, 2020. e-Pub 2020. PMID: 33585199.
- Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer 125(15):2579-2586, 2019. e-Pub 2019. PMID: 30985931.
- Abbas HA, Ravandi F, Loghavi S, Patel KP, Borthakur G, Kadia TM, Jabbour E, Takahashi K, Cortes J, Issa GC, Konopleva M, Kantarjian HM, Short NJ. NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. Am J Hematol 94(6):E158-E160, 2019. e-Pub 2019. PMID: 30838674.
- Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver N, Konopleva M, DiNardo CD, Kadia T, Pemmaraju N, Jabbour E, Cortes J. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. J Hematol Oncol 12(1):1, 2019. e-Pub 2019. PMID: 30606227.
- Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol 36(18):JCO2017776757, 2018. e-Pub 2018. PMID: 29702001.
- Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer 123(22):4391-4402, 2017. e-Pub 2017. PMID: 28743165.
- Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. Clonal chromosomal abnormalities appearing in Philadelphia negative metaphases during CML treatment. Blood 130(19):2084-2091, 2017. e-Pub 2017. PMID: 28835440.
- Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian HM, Jabbour E. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer 123(19):3717-3724, 2017. e-Pub 2017. PMID: 28608976.
- Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol 92(3):238-243, 2017. e-Pub 2017. PMID: 28006851.
- Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer 123(3):459-467, 2017. e-Pub 2017. PMID: 27696391.
- Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, Pierce S, Issa GC, Konopleva M, Kadia TM, Bueso-Ramos C, Khoury JD, Jain N, O'Brien SM, Jabbour E. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 122(24):3812-3820, 2016. e-Pub 2016. PMID: 27508525.
- Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer 122(23):3650-3656, 2016. e-Pub 2016. PMID: 27479888.
- Short NJ, Jabbour E, Sasaki K, Patel K, O'Brien SM, Cortes JE, Garris R, Issa GC, Garcia-Manero G, Luthra R, Thomas D, Kantarjian H, Ravandi F. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 128(4):504-7, 2016. e-Pub 2016. PMID: 27235138.
- Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146(6):904-17, 2011. e-Pub 2011. PMID: 21889194.
- Ghobrial IM, Maiso P, Azab A, Liu Y, Zhang Y, Issa G, Azab F, Sacco A, Quang P, Ngo H, Roccaro A. The bone marrow microenvironment in waldenstrom macroglobulinemia. Ther Adv Hematol 2(4):267-72, 2011. e-Pub 2011. PMID: 23556094.
- Sacco A, Aujay M, Morgan B, Azab AK, Maiso P, Liu Y, Zhang Y, Azab F, Ngo HT, Issa GC, Quang P, Roccaro AM, Ghobrial IM. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. Clin Cancer Res 17(7):1753-64, 2011. e-Pub 2011. PMID: 21355079.
- Sacco A, Maiso P, Azab A, Azab F, Zhang Y, Liu Y, Ngo HT, Morgan B, Quang P, Issa G, Ghobrial IM, Roccaro AM. Key role of microRNAs in Waldenström's macroglobulinemia pathogenesis. Clin Lymphoma Myeloma Leuk 11(1):109-11, 2011. e-Pub 2011. PMID: 21454206.
- Issa GC, Ghobrial IM, Roccaro AM. Novel agents in Waldenström macroglobulinemia. Clin Investig (Lond) 1(6):815-824, 2011. e-Pub 2011. PMID: 22034589.
Review Articles
- Kantarjian, HM, Breccia, M, Haddad, FG, Hehlmann, R, Issa, GC, Malhotra, H, Nicolini, FE, Sasaki, K, Stenke, L, Jabbour, EJ. Management of chronic myeloid leukemia in 2025. Cancer 131(14), 2025. e-Pub 2025. PMID: 40616814.
- Kantarjian, H, Borthakur, G, Daver, N, DiNardo, CD, Issa, GC, Jabbour, EJ, Kadia, TM, Sasaki, K, Short, NJ, Yilmaz, M, Ravandi, F. Current status and research directions in acute myeloid leukemia. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 39300079.
- Cuglievan, B, Kantarjian, HM, Rubnitz, JE, Cooper, T, Zwaan, CM, Pollard, J, DiNardo, C, Kadia, TM, Guest, E, Short, NJ, McCall, DC, Daver, N, Nunez, CA, Haddad, FG, Garcia, MB, Bhalla, K, Maiti, A, Catueno, S, Fiskus, WC, Carter, BZ, Gibson, A, Roth, M, Khazal, SJ, Tewari, P, Abbas, HA, Bourgeois, W, Andreeff, M, Shukla, N, Truong, D, Connors, JS, Ludwig, JA, Stutterheim, J, Salzer, E, Juul-Dam, KL, Sasaki, K, Mahadeo, KM, Tasian, SK, Borthakur, G, Dickson, S, Jain, N, Jabbour, EJ, Meshinchi, S, Garcia-Manero, G, Ravandi, F, Stein, EM, Kolb, EA, Issa, GC. Menin inhibitors in pediatric acute leukemia. Leukemia 38(10):2073-2084, 2024. e-Pub 2024. PMID: 39179671.
- Jen WY, Kantarjian H, Kadia TM, DiNardo CD, Issa GC, Short NJ, Yilmaz M, Borthakur G, Ravandi F, Daver NG. Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease. Br J Haematol 205(1):30-47, 2024. e-Pub 2024. PMID: 38724457.
- Kantarjian H, Branford S, Breccia M, Cortes J, Haddad FG, Hochhaus A, Hughes T, Issa GC, Jabbour E, Nicolini FE, Sasaki K, Xavier-Mahon F. Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?. Leukemia 38(5):947-950, 2024. e-Pub 2024. PMID: 38531949.
- Senapati, J, Sasaki, K, Issa, GC, Lipton, JH, Radich, JP, Jabbour, EJ, Kantarjian, HM. Management of chronic myeloid leukemia in 2023 – common ground and common sense. Blood cancer journal 13(1), 2023. e-Pub 2023. PMID: 37088793.
- Cortes JE, Hochhaus A, Takahashi N, Larson RA, Issa GC, Bombaci F, Ramscar N, Ifrah S, Hughes TP. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncol 18(38):4161-4170, 2022. e-Pub 2022. PMID: 36524980.
- Haddad FG, Issa GC, Jabbour E, Yilmaz M. Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia. Expert Opin Pharmacother 23(7):751-758, 2022. e-Pub 2022. PMID: 35412404.
- Issa GC, Ravandi F, DiNardo CD, Jabbour E, Kantarjian HM, Andreeff M. Therapeutic implications of menin inhibition in acute leukemias. Leukemia 35(9):2482-2495, 2021. e-Pub 2021. PMID: 34131281.
- Issa GC, DiNardo CD. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm. Blood Cancer J 11(6):107, 2021. e-Pub 2021. PMID: 34083508.
- Zarka J, Short NJ, Kanagal-Shamanna R, Issa GC. Nucleophosmin 1 Mutations in Acute Myeloid Leukemia. Genes (Basel) 11(6):1-16, 2020. e-Pub 2020. PMID: 32545659.
- Issa GC, Leblebjian H, Roccaro AM, Ghobrial IM. New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia. Curr Opin Hematol 18(4):260-5, 2011. e-Pub 2011. PMID: 21519243.
- Ghobrial IM, Zhang Y, Liu Y, Ngo H, Azab F, Sacco A, Azab A, Maiso P, Morgan B, Quang P, Issa GC, Leleu X, Roccaro AM. Targeting the bone marrow in Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk 11 Suppl 1(Suppl 1):S65-9, 2011. e-Pub 2011. PMID: 22035751.
- Ghobrial IM, Zhang Y, Liu Y, Ngo H, Azab F, Sacco A, Azab A, Maiso P, Morgan B, Quang P, Issa G, Roccaro A. The bone marrow niche in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk 11(1):118-20, 2011. e-Pub 2011. PMID: 21454209.
- Sacco A, Issa GC, Zhang Y, Liu Y, Maiso P, Ghobrial IM, Roccaro AM. Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology. J Hematol Oncol 3(1):1-5, 2010. e-Pub 2010. PMID: 20929526.
Abstracts
- Richard-Carpentier G, Kantarjian HM, Tang G, Yin CC, Khoury JD, Issa GC, Haddad F, Jain N, Ravandi F, Short NJ, DiNardo CD, Takahashi K, Konopleva MY, Daver NG, Kadia T, Garcia-Manero G, Garris R, O’Brien S, Jabbour E. Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Advances 5(23):5415-5419, 2021. e-Pub 2021.
- Kadia TM, Borthakur G, Pemmaraju N, Daver N, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Bravo GM, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Kanagal-Shamanna R, Takahashi K, Malla R, Marek K, Brandt M, Popat UR, Andreeff M, Cortes JE, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 136(1):17-19, 2020. e-Pub 2020.
- Sasaki K, Kantarjian HM, Issa GC, Garcia-Manero G, Kadia TM, Wierda WG, Yilmaz M, DiNardo CD, Skinner J, Khouri R, Pemmaraju N, Nasnas P, Dellasala S, Pierce SA, Cortes JE, Jabbour E. Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors. Blood 136(1):42-44, 2020. e-Pub 2020.
- Short NJ, Kantarjian HM, Patel K, Kornblau SM, Jorgensen JL, Wang SA, Konopleva MY, Jain N, Kebriaei P, Yilmaz M, Issa GC, Matthews J, Noor M, Garris R, Ravandi F, Jabbour E. Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes. Blood 136(1):26-28, 2020. e-Pub 2020.
- Kim K, Maiti A, Kadia TM, Ravandi F, Daver N, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Alvarado Y, Ferrajoli A, Jabbour E, Jain N, Ohanian M, Takahashi K, Thompson PA, Rausch CR, Montalbano K, Pierce SA, Patel KP, Garcia-Manero G, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of TP53 -Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine. Blood 136(1):33-36, 2020. e-Pub 2020.
- Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz M, Kanagal-Shamanna R, Patel K, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva MY, Daver N, Jabbour E, Yilmaz M, Issa GC, Andreeff M, Kadia TM. Prognostic and Therapeutic Implications of Mutant TP53 Variant Allelic Frequency in Adults with Newly Diagnosed TP53 -Mutated Acute Myeloid Leukemia 136(1):33-34, 2020. e-Pub 2020.
- Sasaki K, Jabbour E, Issa GC, Garcia-Manero G, Kadia TM, Wierda WG, Yilmaz M, DiNardo CD, Skinner J, Khouri M, Pemmaraju N, Nasnas P, Pierce SA, Cortes JE, Kantarjian HM. Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors. Blood 136(1):25+26, 2020. e-Pub 2020.
- Short NJ, Kadia TM, DiNardo CD, Pemmaraju N, Borthakur G, Garcia-Manero G, Jabbour E, Sasaki K, Issa GC, Montalban-Bravo G, Bose P, Burger JA, Miller D, Alexander-Williams L, Ravandi F, Konopleva MY, Kantarjian HM, Daver N. Interim Results of an Open-Label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 Mab, Smoothened Inhibitor, Anti-CD33 Mab, Bcl-2 Inhibitor, and Azacitidine As Single-Agents and As Combinations for Relapsed/Refractory Acute Myeloid Leukemia. Blood 136(1):21-23, 2020. e-Pub 2020.
- Lachowiez C, Konopleva MY, Kadia TM, Daver N, Loghavi S, Wang SA, Adeoti M, Pierce SA, Takahashi K, Short NJ, Sasaki K, Borthakur G, Issa GC, Wierda WG, Pemmaraju N, Bravo GM, Ferrajoli A, Jain N, Masarova L, Yilmaz M, Jabbour E, Garcia-Manero G, Kornblau SM, Ravandi F, Kantarjian HM, DiNardo CD. Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. Blood 136(1):18-20, 2020. e-Pub 2020.
- Alwash Y, Kanagal-Shamanna R, Guerra VA, Daver N, Konopleva M, Ravandi F, Kadia TM, DiNardo CD, Issa GC, Borthakur G, Loghavi S, Takahashi K, Yilmaz M, Maiti A, Kantarjian HM, Kornblau SM, Short NJ. Development of TP53 Mutations over the Course of Acute Myeloid Leukemia Therapy. Blood 136(1):28-29, 2020. e-Pub 2020.
- Maiti A, Konoplev S, DiNardo CD, Kadia TM, Ravandi F, Daver N, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Alvarado Y, Ferrajoli A, Jabbour E, Jain N, Ohanian M, Takahashi K, Thompson PA, Rausch CR, Montalbano K, Pierce SA, Patel KP, Garcia-Manero G, Kantarjian HM, Konopleva MY. Outcomes of De Novo Acute Myeloid Leukemia with Monocytic Differentiation (FAB M4/5) Treated with Venetoclax and Decitabine. Blood 136(1):11-13, 2020. e-Pub 2020.
- Daver N, Basu S, Garcia-Manero G, Abbas H, Konopleva M, Kadia TM, Dinardo CD, Borthakur G, Alotaibi A, Pemmaraju N, Jabbour E, Pierce S, Brandt M, Takahashi K, Ning J, Kornblau S, Sasaki K, Yilmaz M, Issa GC, Short NJ, Matthews J, Flores W, Andreeff M, Cortes J, Ravandi F, Allison JP, Kantarjian HM, Sharma P. Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response. Blood 136(1):43-45, 2020. e-Pub 2020.
- Guerra V, Perez JM, Hammond D, Chien KS, Kanagal-Shamanna R, Naqvi K, Sasaki K, Paul S, Kadia TM, DiNardo CD, Konopleva MY, Daver N, Ravandi F, Pemmaraju N, Short NJ, Issa GC, Takahashi K, Estrov ZE, Pierce SA, Kantarjian HM, Garcia-Manero G, Bravo GM. Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure. Blood 136(1):22-23, 2020. e-Pub 2020.
- Montalban Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Short NJ, Issa GC, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov ZE, Khoury JD, Loghavi S, Pierce S, Garcvia-Manero G. Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia. Blood 136(1):54-56, 2020. e-Pub 2020.
- Maiti A, DiNardo CD, Ravandi F, Pemmaraju N, Borthakur G, Bose P, Issa GC, Kadia TM, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour E, Jain N, Ohanian M, Takahashi K, Thompson PA, Rausch CR, Montalbano KS, Pierce SA, Kantarjian HM, Daver N, Konopleva MY. Venetoclax, FLT3 Inhibitor and Decitabine in FLT3 mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial. Blood 136(1):53-55, 2020. e-Pub 2020.
- Maiti A, DiNardo CD, Wang SA, Jorgensen JF, Kadia TM, Daver N, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour E, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano K, Pierce SA, Kantarjian HM, Konopleva M, Ravandi F. Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia. Blood 136(1):22-25, 2020. e-Pub 2020.
- Rafei H, Kantarjian HM, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Wang SA, Jorgensen JL, Khouri IF, Kebriaei P, Champlin RE, Jain N, Dabaja BS, Issa GC, Pemmaraju N, Kadia TM, Paul S, Jammal N, Garcia-Manero G, Wierda WG, DiNardo CD, Daver N, Montalban-Bravo G, Khouri R, Nasnas P, Thompson PA, Jacob J, Rostykus M, Garris R, Konopleva MY, O, Brien SM, Jabbour E. Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study. Blood 136(1):39-41, 2020. e-Pub 2020.
- Morita K, Sasaki K, Richard-Carpentier G, Konopleva M, Huang X, Short NJ, Jain N, Ravandi F, Dabaja BS, Daver N, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang SA, Khoury JD, Jorgensen JL, Champlin RE, Khouri IF, Kebriaei P, Schroeder HM, Khouri M, Takahashi K, O’Brien SM, Kantarjian HM, Jabbour E. Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis. Blood 136(1):42-43, 2020. e-Pub 2020.
- Hammond D, Loghavi S, Konopleva MY, Kadia TM, Daver N, Ohanian M, Issa GC, Alvarado Y, Montalban-Bravo G, Garcia-Manero G, Borthakur G, Ravandi F, Takahashi K, Kantarjian HM, DiNardo CD. Response Patterns and MRD By Flow Cytometry and NGS in Patients with Mutant-IDH Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents. Blood 136(1):35-36, 2020. e-Pub 2020.
- Kadia TM, Pemmaraju, N, Yilmaz M, Li L, Lyu M, Huang M, Zeng K, Parmar S, DiNardo CD, Daver N, Issa GC, Jabbour E, Borthakur G, Verstovsek S. Adoptive Therapy with Allogeneic Cord Blood T Regulatory Cells Show Safety and Early Clinical Signal in Primary Myelofibrosis. Blood 136(1):41-42, 2020. e-Pub 2020.
- Yilmaz M, Alfayez M, Kadia TM, DiNardo CD, Borthakur G, Loghavi S, Konopleva MY, Kanagal-Shamanna R, Patel K, Jabbour E, Garcia-Manero G, Pemmaraju N, Pierce SA, Issa GC, Short NJ, Bravo GM, Takahashi K, Assi R, Alotaibi AS, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Outcomes with Sequential FLT3-Inhibitor (FLT3i) Based Therapies in Patients (pts) with FLT3 -Mutated Acute Myeloid Leukemia (AML) Exposed to Prior FLT3i Based Therapies. Blood 136(1):22-24, 2020. e-Pub 2020.
- Morita K, Kantarjian HM, Ravandi F, Sasaki K, Jain N, Konopleva MY, Short NJ, Takahashi K, Khouri R, Nasnas P, DiNardo CD, Kadia TM, Garcia-Manero G, Daver N, Bravo GM, Issa GC, Cortes JE, Jabbour E. Outcome of Patients with Chronic Myeloid Leukemia in Lymphoid Blast Crisis (CML-LBC) and Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with Hyper-CVAD and Dasatinib. Blood 136(1):46-48, 2020. e-Pub 2020.
- Abou Dalle I, Paranal R, Paul S, Li W, Ning J, Cortes JE, Jabbour E, Kantarjian HM, Issa GC. Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. J Clin Oncol 37 37(15):7039-7039, 2019. e-Pub 2019.
- Preetesh J, Kanagal-Shamanna R, Kantarjian HM, San Lucas A, Ghorab A, Jabbour EJ, Issa GC, Sasaki K, Kadia T, Estrov Z, Ravandi F, and Cortes JE. Pattern of Mutational Changes in Patients with Chronic Phase Cml Who Are Treated with Frontline Tki and Transform to Blast Phase Cml. Blood 130(1):4172, 2017. e-Pub 2017.
- Issa, GC, Kantarjian HM, Wang F, Gonzalez G, Borthakur G, Tang G, Bueso-Ramos C, Kanagal R, Hidalgo J, Zhao C, Coyle M, Takahashi K, Jain P, Ravandi F, Kadia T, Garcia-Manero G, Jabbour E, Futreal PA, Cortes JE. Clinical and Molecular Characterization of Clonal Chromosomal Abnormalities Appearing in Philadelphia- Negative Metaphases of Chronic Phase Cml. Blood 130(1):47, 2017. e-Pub 2017.
- Sasaki K, Jabbour EJ, Khouri K, Thomas DA, Garcia-Manero G, Ravandi F, Borthakur G, Short NJ, Issa GC, Kadia T, Jones E, Garris R, Cortes JE, O'Brien SM, and Kantarjian HM. Phase Ii Study of Hyper-Cmad with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. ALL 17(2):S266, 2017. e-Pub 2017.
- Issa GC, Kantarjian HM, Short NJ, Ravandi F, Huang X, Garcia-Manero G, Plunkett P, Gandhi V, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Dinardo C, Brandt M, O'Brien SM, Cortes JE, Jabbour E. Idarubicin and cytarabine with clofarabine or fludarabine in adults with newly diagnosed acute myeloid leukemia: updated results of a randomized phase II study. JCO Glob Oncol 15:7037-7037, 2017. e-Pub 2017.
- Issa GC, Leblebjian H, Roccaro AM, Ghobrial IM. Distinct patterns of somatic mutation clearance and association with clinical outcome in patients with AML. American Society of Clinical Oncology Annual Meeting 35(15):7005-7005, 2017. e-Pub 2017.
- Maiti A, Kantarjian HM, Ravandi F, Thomas D, Khouri M, Garcia-Manero G, Garris R, Cortes JE, Short NJ, Sasaki K, Issa GC, Koller PB, Schroeder HM, Kadia TM, Verstovsek S, Daver N, Jain N, Konopleva M, O'Brien SM, Jabbour E. Updated Results of Frontline Ofatumumab-Hyper-CVAD in Adults with CD20+ Acute Lymphoblastic Leukemia. American Society of Clinical Oncology Annual Meeting 35(15):7033-7033, 2017. e-Pub 2017.
- Maiti A, Kantarjian HM, Ravandi F, Khouri M, Thomas DA, Garcia-Manero G, Garris R, Cortes JE, Short NJ, Jain N, Bose P, Verstovsek S, Konopleva M, Sasaki K, Issa GC, Ghosn M, Schroeder HM, Kadia T, Daver N, O'Brien SM, and Jabbour EJ. Hyper-Cvad Plus Ofatumumab as Frontline Therapy in Cd20+ Acute Lymphoblastic Leukemia: Updated Results of a Phase Ii Trial. Blood 130(1):3876, 2017. e-Pub 2017.
- Kiyomi M, Wang F, Patel K, Bueso-Ramos C, Issa GC, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Ravandi F, Kadia T, Daver N, Konopleva M, Andreeff M, Cortes JE, Garcia-Manero G, Jabbour EJ, Futreal PA, Kantarjian HM, and Takahashi K. Persistent Somatic Mutation at Remission Is Associated with Poor Survival and Higher Risk of Relapse in Patients with Acute Myeloid Leukemia. Blood 130(1):2667, 2017. e-Pub 2017.
- Benton CB, Takahashi K, Bose P, Wang F, Chen H, Zheng X, Zhang J, Wang X, Su X, Montalban-Bravo G, Issa GC, Daver N, Jabbour E, DiNardo, Bueso-Ramos C, MD, Patel K, Kornblau S, MD1, Konopleva M, Borthakur G, Kadia TM, Cortes JE, Ravandi F, Andreeff M, Garcia-Manero M, Futreal A, Kantarjian HM. Archetypes of AML Defined Using Whole Exome Sequencing and Clinical Characteristics in a Diverse Group of Patients. Blood 128(22):597, 2016. e-Pub 2016.
- Short NJ, Jabbour E, Sasaki K, Patel K, O’Brien SM, Cortes JE, Garris R, Issa GC, Garcia-Manero G, Luthra R, Thomas D, Kantarjian HM, Ravandi F. Impact of complete molecular response (CMR) on survival in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Blood 128(4):504-507, 2016. e-Pub 2016.
- Sasaki K, Kantarjian H, Thomas D, Ravandi F, Khouri M, Cortes J, Pemmaraju N, Kadia T, Short N, Issa GC, Garris R. Frontline Therapy with Combination of Hyper-CVAD with Ponatinib in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) ALL (ALL): A Phase II Study. Clin Lymphoma Myeloma Leuk 16(S10):1, 2016. e-Pub 2016.
- Maiti A, Kantarjian HM, Ravandi F, Thomas D, Khouri M, Garcia-Manero G, Garris R, Cortes JE, Short NJ, Sasaki K, Issa GC, Koller PB, Schroeder HM, Kadia TM, Verstovsek S, Daver N, Jain N, Konopleva M, O'Brien SM, Jabbour E. Complex Karyotype and Low Hypodiploidy/Near Triploidy are Adverse Prognostic Factors in Adult ALL (ALL) Independent of MRD Status. Clin Lymphoma Myeloma Leuk 16(S7), 2016. e-Pub 2016.
- Short NJ, Jabbour, Cortes JE, Garris R, O'Brien SM, Patel K, Sasaki K, Issa GC, Garcia-Manero G, Thomas DA, Kantarjian HM, Ravandi F. Impact of complete molecular response (CMR) on survival in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Blood 128(4):504-7, 2016. e-Pub 2016.
- Short NJ, Jabbour, Cortes JE, Garris R, O'Brien SM, Patel K, Sasaki K, Issa GC, Garcia-Manero G, Thomas DA, Kantarjian HM, Ravandi F. Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). JCO Glob Oncol 34(15):7036-7036, 2016. e-Pub 2016.
- Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Garcia-Manero G, Thomas DA, Pierce S, Issa GC, Cortes JE, Kadia TM, Jain N. Prognostic significance of day 14 (D14) bone marrow (BM)assessment in adult patients receiving induction for Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). 2016 ASCO Annual Meeting 34(15):7035-7035, 2016. e-Pub 2016.
- Issa GC, Kantarjian HM, Ravandi F, Thomas D, Khouri M, Garcia Manero G, Garris R, Cortes JE, Short NJ, Sasaki K, Schroeder H, Kadia T, Verstovsek S, Daver N, Jain N, Konopleva M, O'Brien SM, Jabbour E. Updated Results from the Phase II Study of Hyper-CVAD in Combination with Ofatumumab as Frontline Therapy for Adults with CD20 Positive (CD20+) ALL. Clinical Lymphoma, Myeloma and Leukemia Volume 16, S6, 2016. e-Pub 2016.
- Short NJ, Jabbour, Cortes JE, Garris R, O'Brien SM, Patel K, Sasaki K, b|Issa GC, Garcia-Manero G, Thomas DA, Kantarjian HM, Ravandi F. Propensity score analysis: Frontline therapy with hyper-CVAD (HCVAD) + ponatinib vs. HCVAD + dasatinib in patients(pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). JCO Glob Oncol 34(15), 2016. e-Pub 2016.
- Issa GC, Kantarjian HM, Yin CC, Ravandi F, Garcia-Manero G, Thomas DA, Cortes JE, Short NJ, Sasaki K, Qiao W, Takahashi K, Pierce S, Verstovsek S, Kadia TM, Borthakur G, O'Brien SM, Jabbour E. Prognostic impact of pre-treatment cytogenetics in adult acute lymphoblastic leukemia (ALL). American Society of Clinical Oncology Annual Meeting; 2016 34(15), 2016. e-Pub 2016.
- Short NJ, Kantarjian HM, Sasaki K, Khouri M, Cortes J, Ravandi F, Thomas D, Garcia- Manero G, Khouri I, Kebriaei P, Champlin R, Pierce S, Issa GC, Konopleva M, Kadia T, Bueso-Ramos C, Khoury J, Jain N, O'Brien SM, Jabbour E. Complex Karyotype and Low Hypodiploidy/Near Triploidy are Adverse Prognostic Factors in Adult ALL (ALL) Independent of MRD Status. Clin Lymphoma Myeloma Leuk 16(S14), 2016. e-Pub 2016.
- Issa GC, Kantarjian HM, Jabbour E, Borthakur G, Verstovsek S, Pierce S, Wierda W, Ferrajoli A, Garcia-Manero G, Kadia T, Daver N, Pemmaraju N, Ravandi F, DellaSala SE, Cortes JE. Additional Chromosomal Abnormalities in Philadelphia Chromosome Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia. Blood 126(23):1577, 2015. e-Pub 2015.
- Koichi T, Wang F, Sahil S, Zhang J, Gumbs C, Issa GC, Benton CB, Pierce S, Jabbour E, Daver N, KadiaT, DiNardo C, Kantarjian HM, Futreal PA, Garcia-Manero G. Presence of 4 or More Driver Mutations Predicts Poor Response to Hypomethylating Agent (HMA) Therapy and Poor Overall Survival in MDS. Blood 126(23):1663, 2015. e-Pub 2015.
- Abdel AK, Hu J, Quang J, Azab F, Pitsillides C, Thompson B, Maiso P, Roccaro AM, Sacco A, Ngo HT, Issa GC, Lin C, Kung AL, Vanderkerken K, Ghobrial IM. Hypoxia Promotes Dissemination of Multiple MyelomaThrough Acquisition of Endothelial to Mesenchymal Transition (EMT) Features. Blood 119(24):1-56, 2012. e-Pub 2012.
- Roccaro AM, Sacco A, Azab AK, Tai YT, Maiso P, Zhang Y, Liu Y, Reagan M, Azab F, Issa GC, Ngo HT, Quang P, Anderson KC, Dalla-Favera R, Ghobrial IM. Stroma-Derived Exosomes Mediate Oncogenesis in Multiple Myeloma. Stroma-Derived Exosomes Mediate Oncogenesis in Multiple Myeloma. Blood 118(21):625, 2011. e-Pub 2011.
- Issa GC, Jake DE, Micheal MR, Madeleine LE, Rahl PB, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Shi J, Chesi M, Schinzel AC, Vakoc CR, Bergsagel PL, Richardson PG, Young R, Hahn W, Ghobrial IM, Anderson KC, Kung AL, Mitsiades CS, and Bradner JE. Inhibition of c-Myc Expression and Function in Hematologic Malignancies. Blood 118(21):1409, 2011. e-Pub 2011.
Letters to the Editor
- Swaminathan, M, DiNardo, C, Maiti, A, Pemmaraju, N, Ohanian, M, Daver, NG, Garcia-Manero, G, Issa, GC, Borthakur, G, Ravandi-Kashani, F, Montalban Bravo, G, Kadia, TM, Alvarado, Y, Jabbour, EJ, Short, NJ, Wierda, WG, Jain, N, Kornblau, SM, Masarova, L, Pierce, S, Qiao, W, Ning, J, Kantarjian, HM, Konopleva, M. VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome. Blood cancer journal 15, 2025.
- Senapati, J, Garcia-Manero, G, DiNardo, C, Deshmukh, I, Borthakur, G, Kadia, TM, Jabbour, EJ, Short, NJ, Abbas, HA, Pemmaraju, N, Jain, N, Haddad, FG, Issa, GC, Maiti, A, Shpall, E, Popat, UR, Loghavi, S, Tang, G, Yilmaz, M, Alvarado, Y, Montalban Bravo, G, Ravandi-Kashani, F, Kantarjian, HM, Daver, N. Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia. Bone marrow transplantation 60: 910-913, 2025.
- Ravandi, F, Senapati, J, Jain, N, Short, NJ, Kadia, TM, Borthakur, G, Konopleva, M, Wierda, WG, Huang, X, Maiti, A, Issa, GC, Balkin, H, Garris, R, Ferrajoli, A, Garcia-Manero, G, Alvarado, Y, Kebriaei, P, Jabbour, EJ, Kantarjian, HM. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia 38: 2717-2721, 2024.
- Mustafayev, K, Yepez Guevara, E, DiNardo, CD, Jabbour, EJ, Issa, GC, Ratan, R, Pemmaraju, N, Torres, HA. Virologic effect and hepatotoxicity of BCR::ABL1 tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study. Leukemia Research 147, 2024.
- Jen, WY, Jabbour, EJ, Short, NJ, Issa, GC, Haddad, FG, Jain, N, Pemmaraju, N, Daver, N, Masarova, L, Borthakur, G, Chien, KS, Garris, R, Kantarjian, H. A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. American journal of hematology 99: 2229-2232, 2024.
- Haddad FG, Nasnas C, Sasaki K, Paul S, Issa GC, Rausch C, Jabbour E, Kantarjian H. Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib. Clin Lymphoma Myeloma Leuk 24: 484-487, 2024.
- Short NJ, Jabbour E, Nasr LF, Jain N, Haddad FG, Issa GC, Sasaki K, Senapati J, Kebriaei P, Garris R, Konopleva M, Ravandi F, Kantarjian H. Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy. Am J Hematol 99: 1423-1426, 2024.
- Haddad FG, Sasaki K, Issa GC, Jabbour E, Kantarjian H. The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in chronic myeloid leukemia. Am J Hematol 99: 1175-1176, 2024.
- Montalban-Bravo G, Rodriguez-Sevilla JJ, Swanson DM, Kanagal-Shamanna R, Hammond D, Chien K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia 38: 1178-1181, 2024.
- Bataller A, DiNardo CD, Bazinet A, Daver NG, Maiti A, Borthakur G, Short N, Sasaki K, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol 99: 792-796, 2024.
- Bataller, A, Abuasab, T, McCall, DC, Wang, W, Cuglievan, B, Issa, GC, Jabbour, EJ, Short, NJ, DiNardo, C, Tang, G, Garcia-Manero, G, Kantarjian, HM, Sasaki, K. Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineage-directed therapies. Haematologica 109: 293-297, 2024.
- Hammond, DE, Loghavi, S, Wang, SA, Konopleva, M, Kadia, TM, Daver, N, Ohanian, M, Issa, GC, Alvarado, Y, Short, NJ, Sasaki, K, Pemmaraju, N, Montalban Bravo, G, Lachowiez, C, Maiti, A, Garcia-Manero, G, Jabbour, EJ, Borthakur, G, Ravandi-Kashani, F, Takahashi, K, Pierce, SR, Kantarjian, HM, DiNardo, C. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood cancer journal 13, 2023.
- Haddad, FG, Bidikian, A, Issa, GC. Reply to “Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia. Cancer.
Patient Reviews
CV information above last modified September 04, 2025